Sitemap

Pages

• About
  • Board Committees
  • Board of Directors
  • Diversity, Equity & Inclusion
  • Leadership Team
  • Sustainability
• Capabilities
  • Analytical Services
  • Clinical Trial Services
    • Download – Focused, Flexible, and Responsive Clinical Trial Services
  • Commercial Manufacturing
  • Commercial Packaging and Logistics
  • Facilities & Equipment
  • Formulation Development
  • Packaging and Logistics
  • Quality Assurance
    • Quality Confirmation
  • Regulatory Support
  • Technology Transfer
    • Technology Transfer Confirmation
• Careers
• Contact Us
  • Thank you for your inquiry
  • Thank you for your inquiry
• Disclaimer
• Home
• Knowledge Center
  • Blog
  • Case Studies
    • Innovative Reformulation of a Complex, High-Drug-Load, Modified Release Dosage Form With Reduced Dosing Frequency
    • Opioid Reformulated for Abuse Deterrence – Filed as a CMC Supplement in Less Than a Year
  • Choosing a CDMO for Your Reformulation Needs
    • Download Choosing a CDMO for Your Reformulation Needs
  • Fact Sheets
    • Choosing a CDMO for Your Reformulation Needs
      • Download – Choosing a CDMO for Your Reformulation Needs
    • New Product Filing Strategies: Questions to Ask Your CDMO
      • Download – New Product Filing Strategies: Questions to Ask Your CDMO
    • Recro Fact Sheet
      • Download – Recro Site Fact Sheet
  • How to Select the Right Polymers for Your Modified Release Tablet or Capsule
    • Download – How to Select the Right Polymers for Your Modified Release Tablet or Capsule
  • New Product Filing Strategies: Questions to Ask Your CDMO
    • Download New Product Filing Strategies: Questions to Ask Your CDMO
  • Site Information
    • Download Case Study – Opioid Reformulated for Abuse Deterrence – Filed as a CMC Supplement in Less Than a Year
    • Download Case Study – Innovative Reformulation of a Complex, High-Drug-Load, Modified Release Dosage Form With Reduced Dosing Frequency
    • Download Recro Site Fact Sheet
  • Webinars
    • Avoiding Potential Pitfalls: Phase Appropriate CMC Development and Regulatory Considerations
    • How To Select the Right Polymers for Your Modified Release Tablet or Capsule
    • Regulatory and CMC Considerations for Developing Modified Release Versions of Immediate Release Oral Solid Dosage Forms
  • White Papers
    • Choosing a Formulation and Process Approach to Oral Controlled Release
      • Download Choosing a Formulation and Process Approach to Oral Controlled Release
    • Download White Paper – How to Avoid Last-Minute CMC Roadblocks to Approval
    • Download White Paper – Optimizing Operations in Multiproduct Pharma Manufacturing Facilities
    • Download White Paper – Oral Controlled Release White Paper
    • Download White Paper – Wurster Processing for Modified Release
    • How to Avoid Last Minute CMC Roadblocks to Approval
    • Optimizing Operations in Multiproduct Pharma Manufacturing Facilities
    • Oral Controlled Release
    • Serialization: Optimizing, Planning and Implementation
      • Download Serialization: Optimizing, Planning and Implementation
    • The Recro Approach to Proactive Improvement in Established QC Laboratory Processes
      • Download White Paper – The Recro Approach to Proactive Improvement in Established QC Laboratory Processes
    • Wurster Processing for Modified Release
• Modified Release
• News & Events
  • Events
  • News
• Privacy Policy
• Request a Site Visit
• Search
• Sitemap
• Thought Leadership
• Virtual Meeting & Tour

Posts by category

• Category: Clinical Trial Materials
  • No More Missed Milestones: The Benefits of Clinical Trial Materials and Clinical Trial Supplies Consolidation
• Category: Clinical Trial Services
  • Careful and Proactive Planning of Packaging and Distribution Strategy Saves Time and Cost
• Category: Clinical Trial Supplies
• Category: Excipient Selection
  • Excipient Selection for Successful Formulation Development of Modified Release Oral Solid Dosage Forms
• Category: Formulation Development
  • How to Select the Right Polymers for Your Modified Release Multiparticulate Capsule
  • How to Select the Right Polymers for Your Modified Release Tablet
  • Successful Formulation Development of Modified Release Oral Solid Dosage Forms: Release Profiles, High Drug Loads, and Delivery Systems
• Category: Modified Release
  • 3 Examples of Multiparticulates Enabling Performance a Matrix Tablet Can’t
  • Pros and Cons of Matrix vs. Multiparticulate Formulations
  • 6 Considerations for Developing Modified Release Versions of Immediate Release Oral Solid Dosage Forms
• Category: Operations
  • How to Maintain Accuracy, Consistency, and On-Time Delivery in the QC Lab
• Category: Oral Solid Dosage
• Category: Quality Control
• Category: Regulatory
• Category: Release Profile

News

• Recro Signs Renewable Energy Agreement With Georgia Power
• Recro and BioCorRx Expand Development and Manufacturing Relationship to Support BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder
• Recro to Host Webcast to Discuss Acquisition of San Diego-Based IRISYS
• Recro Announces Acquisition of San Diego-based IRISYS, Creating Bi-Coastal, Full Service CDMO
• Recro Announces Entry Into Letter of Intent for Acquisition of a Full Service CDMO
• Recro Reports Second Quarter 2021 Financial Results
• Recro To Report Financial Results for Second Quarter 2021 on August 9, 2021
• Recro Appoints Erica Raether as Vice President of People, Culture and ESG
• Recro Enters Development and Manufacturing Agreement With New Client
• Recro Reports Inducement Grants for New Staff
• Recro Appoints Laura L. Parks, Ph.D. to Board of Directors
• Recro Expands Capabilities for Growing Clinical Trial Services (CTS) Offerings
• Recro Enters Development Agreement With Astex Pharmaceuticals
• Recro Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
• Recro Announces Pricing of $30.0 Million Public Offering of Common Stock
• Recro Announces Proposed Public Offering of Common Stock
• Recro Reports First Quarter 2021 Financial Results
• Recro to Report Financial Results for First Quarter 2021 on May 6
• Recro Expands Development and Manufacturing Relationship With Ensysce Biosciences
• Recro Reports Inducement Grants for New Staff
• Recro Strengthens Business Development Team to Drive Customer Growth and Diversification
• Recro to Present at H.C. Wainwright Global Life Science Conference
• Recro Reports Fourth Quarter and Year End 2020 Financial Results
• Recro to Report Fourth Quarter and Year-End 2020 Financial Results Earlier Than Previously Announced
• Recro Announces Amendment to Athyrium Credit Facility
• Recro to Report Financial Results for Fourth Quarter And Year-End 2020 on February 26
• Recro Strengthens Leadership Team With Key Executive and Board Appointments
• Recro Grants Inducement Award to New Chief Executive Officer
• Recro Announces Executive Changes
• Recro Reports Third Quarter 2020 Financial Results
• Recro to Report Third Quarter 2020 Financial Results and Host Conference Call and Webcast on November 9, 2020
• Recro to Present at Oppenheimer Fall Healthcare Life Sciences & Medtech Summit
• Recro Reports Second Quarter 2020 Financial Results
• Recro to Report Second Quarter 2020 Financial Results and Host Conference Call and Webcast on August 10, 2020
• Recro Highlights Manufacturing Readiness For Essential Drugs and Medical Supplies
• Regulatory and CMC Considerations for Developing Modified Release Versions of Immediate Release Oral Solid Dosage Forms, Upcoming Webinar Hosted by Xtalks
• Recro Reports First Quarter 2020 Financial Results and Provides Update on COVID-19 Response and Impact
• Recro to Report First Quarter 2020 Financial Results and Host Conference Call and Webcast on May 11, 2020
• Recro Announces Change in Location of its 2020 Annual Meeting of Shareholders to its Corporate Headquarters
• COVID-19
• Recro Reports Financial Results for the Year Ended 2019
• Recro to Report Year End 2019 Financial Results and Host Conference Call and Webcast on March 4, 2020
• Recro Completes Separation of Baudax Bio and Becomes a Dedicated Contract Development and Manufacturing Organization
• Baudax Bio™ Launches as a New Pharmaceutical Company Aimed at Advancing Promising, Non-Opioid Analgesic Therapies
• Recro Pharma Announces Effectiveness of Baudax Bio Form 10 Registration Statement
• Recro Pharma Reports Third Quarter 2019 Financial Results
• Recro Pharma to Report Third Quarter 2019 Financial Results and Host Conference Call and Webcast on November 8, 2019
• Recro Pharma’s Board of Directors Approves Separation of Acute Care Business Segment and Declares Special Dividend Distribution of Baudax Bio Common Stock
• FDA Grants Appeal to Recro Pharma for IV Meloxicam New Drug Application
• Recro Pharma Reports Second Quarter 2019 Financial Results
• Recro Pharma to Report Second Quarter 2019 Financial Results and Host Conference Call and Webcast on August 8, 2019
• Avoiding Potential Pitfalls: Phase Appropriate CMC Development and Regulatory Considerations, New Webinar Hosted by Xtalks
• Recro Pharma to Present at Upcoming Investor Conferences
• Recro Pharma Reports First Quarter 2019 Financial Results
• Recro Pharma to Report First Quarter 2019 Financial Results and Host Conference Call and Webcast on May 10, 2019
• Recro Pharma Announces Six-Year Extension of License and Supply Agreement Between Teva and Recro
• Recro Pharma Announces Presentation of New Meta-Analysis for IV Meloxicam at the 44th Annual Regional Anesthesiology and Acute Pain Medicine Meeting
• Recro Pharma Restructures Acute Care Segment While Continuing To Execute on Strong CDMO Segment Performance
• Recro Pharma Appoints Arnaud Ajdler to Its Board of Directors
• Recro Pharma Receives Complete Response Letter from the FDA for Intravenous Meloxicam
• Recro Pharma to Host Educational Symposium on Pain Management Options in Total Joint Replacements at the American Academy of Orthopaedic Surgeons 2019 Annual Meeting
• Recro Pharma Obtains $40.5 Million of Non-Dilutive Capital Through Expanded Credit Facility
• Recro Pharma Announces Publication of Phase III IV Meloxicam Clinical Safety and Opioid Use Data in the Journal Clinical Pharmacology in Drug Development
• Recro Pharma Announces New IV Meloxicam Data Publication in the Journal Regional Anesthesia & Pain Medicine
• Recro Pharma Reports Financial Results for the Fourth Quarter and Year End 2018
• Recro Pharma to Report Fourth Quarter and Year End 2018 Financial Results and Host Conference Call and Webcast on February 19, 2019
• Recro Pharma Announces Five-Year Manufacturing and Supply Agreement Between Novartis and Recro
• Recro Pharma Amends Athyrium Credit Facility
• Recro Pharma Amends IV Meloxicam License Agreement with Alkermes
• Recro Pharma Announces Presentation of New Data Demonstrating IV Meloxicam’s Effect on Platelet Function at the 72nd PostGraduate Assembly in Anesthesiology
• Recro Pharma Announces Publication of Phase II IV Meloxicam Abdominal Hysterectomy Data in Anesthesia & Analgesia
• Recro Pharma to Participate in Upcoming Investor Conferences
• Recro Pharma Reports Third Quarter 2018 Financial Results Raising Guidance for CDMO business for 2018
• Recro Adds New Facility, Broadens Capabilities With High-Potent Processing on Deck
• Recro Pharma to Report Third Quarter 2018 Financial Results and Host Conference Call and Webcast on November 7, 2018
• Recro Pharma Announces PDUFA Date for IV Meloxicam
• Recro Announces Expansion of CDMO Service Capabilities
• Recro Pharma to Participate in Upcoming Investor Conferences
• Recro Pharma to Present IV Meloxicam Data at PAINWeek® 2018
• Recro Pharma Provides Regulatory Update for IV Meloxicam
• Recro Pharma Reports Second Quarter 2018 Financial Results
• Recro Pharma to Report Second Quarter 2018 Financial Results and Host Conference Call and Webcast on August 7, 2018
• Recro Pharma Announces Publication of Phase III IV Meloxicam Abdominoplasty Data in Plastic and Reconstructive Surgery Global Open Journal
• Recro Pharma Receives Complete Response Letter from the FDA
• Recro Pharma Reports First Quarter 2018 Financial Results
• Recro Pharma Announces Receipt of Issue Notifications for Three New Patents for IV Meloxicam
• Recro Pharma Announces Commercial Team Additions
• Recro Pharma to Report First Quarter 2018 Financial Results and Host Conference Call and Webcast on May 9, 2018
• Recro Pharma Presents Data for Neuromuscular Blocking and Reversal Agents at the AUA 2018 Annual Meeting
• Recro Hires Industry Veteran to Lead Business Development Team
• Recro Pharma to Present IV Meloxicam Data at the 43rd Annual Regional Anesthesiology and Acute Pain Medicine Meeting
• Recro Pharma Announces Commercial Team Additions
• Recro Pharma Announces Publication of Phase III IV Meloxicam Bunionectomy Data in the Clinical Journal of Pain
• Recro Pharma to Present at the 17th Annual Needham Healthcare Conference
• Recro Pharma to Present at Upcoming Investor Conferences
• Recro Pharma Announces an Educational Symposium on Challenges in Acute Pain Management and Advances in Evidence-Based Management Approaches at the American Academy of Orthopaedic Surgeons 2018 Annual Meeting
• Recro Pharma Announces Commercial Team Additions
• Recro Pharma Reports Year End 2017 Financial Results
• Recro Pharma to Host Analyst and Investor Day on February 28, 2018
• Recro Pharma to Host Analyst and Investor Day on February 28, 2018
• Recro Pharma Announces Publication of Supportive Phase II IV Meloxicam Bunionectomy Data in the Journal of Pain Research
• Recro Pharma Announces Key Sales Team Additions
• Recro Pharma Announces Publication of Supportive Phase II IV Meloxicam Data in the Journal of Clinical Pharmacology
• Recro Pharma Announces Key Executive Promotions to the Financial Team
• Recro Pharma Reports Inducement Grants for New Staff
• Recro Pharma Secures $100 Million Credit Facility
• Recro Pharma Reports Third Quarter 2017 Financial Results
• Recro Pharma to Present at Upcoming Investor Conferences
• Recro Pharma Reports Inducement Grants for New Staff
• Recro Pharma Presents Phase III IV Meloxicam Clinical Efficacy Data in Patients Following Abdominoplasty at the 2017 American Society of Plastic Surgeons Annual Meeting
• Recro Pharma to Participate in Upcoming Investor Conferences
• Recro Pharma Announces PDUFA Date for IV Meloxicam 30mg
• Recro Pharma Reports Inducement Grants for New Staff
• Recro Pharma Announces FDA Acceptance for Review of New Drug Application for IV Meloxicam 30mg
• Recro Pharma Presents Phase III IV Meloxicam Clinical Safety and Opioid Use Data at PAINWeek® 2017
• Recro Pharma Appoints Jyrki Mattila as Executive Vice President of Business Development
• Recro Pharma Reports Inducement Grants for New Staff
• Recro Pharma Reports Second Quarter 2017 Financial Results
• Recro Pharma Submits New Drug Application for IV Meloxicam 30mg
• Recro Pharma Reports Inducement Grants for New Staff
• Recro Pharma Reports Inducement Grants for New Staff
• Recro Pharma Acquires Novel Neuromuscular Blocking Agents
• Recro Pharma Added to the Russell 3000® Index
• Recro Pharma to Participate in Hospital Drug Launch Panel at the JMP Life Sciences Conference
• Recro Pharma Reports Inducement Grants for New Staff
• Recro Pharma Appoints Ryan D. Lake as Senior Vice President of Finance and Chief Accounting Officer
• Recro Pharma to Participate in Upcoming Investor Conferences
• Recro Expands Manufacturing Capabilities
• Recro Pharma Presents Phase III Bunionectomy Clinical Data for IV Meloxicam at the American Pain Society 36th Annual Scientific Meeting
• Recro Pharma to Present Phase III Bunionectomy Clinical Data for IV Meloxicam at the American Pain Society 36th Annual Scientific Meeting
• Recro Pharma Reports First Quarter 2017 Financial Results
• Recro Pharma Announces Successful Top-Line Results from Phase III Safety Study of IV Meloxicam
• Recro Pharma to Present at the 16th Annual Needham Healthcare Conference
• Recro Pharma to Present at the Oppenheimer 27th Annual Healthcare Conference
• Recro Pharma Reports Year End 2016 Financial Results
• Recro Pharma Appoints Bryan Reasons to Its Board of Directors
• Recro Pharma to Present at Upcoming Investor Conferences
• Recro Pharma Completes Enrollment in Phase III Safety Study of IV Meloxicam
• Recro Pharma Announces Closing of $40 Million Public Offering of Common Stock
• Recro Pharma Announces Pricing of Public Offering of Common Stock
• Recro Pharma Announces Proposed Public Offering of Common Stock
• Recro Pharma Reports Positive Top-Line Results from Pivotal Phase III Clinical Trial of IV Meloxicam
• Recro Pharma Reports Third Quarter 2016 Financial Results
• Recro Pharma to Present at Upcoming Investor Conferences
• Recro Pharma Presents Clinical Data at PAINWeek 2016
• Recro Pharma to Present at the Rodman & Renshaw 18th Annual Global Investment Conference
• Recro Pharma Announces Closing of Public Offering of Common Stock
• Recro Pharma Announces Pricing of Public Offering of Common Stock
• Recro Pharma Announces Proposed Public Offering of Common Stock
• Recro Pharma Reports Second Quarter 2016 Financial Results
• Recro Pharma Reports Positive Top-Line Results from Pivotal Phase III Clinical Trial of IV Meloxicam
• Recro Pharma Appoints Michael Celano as Chief Financial Officer
• Recro Pharma to Present at the Jefferies 2016 Global Healthcare Conference
• Recro Pharma Reports First Quarter 2016 Financial Results
• Recro Pharma Presents Clinical Data at American Pain Society 35th Annual Scientific Meeting
• Recro Pharma Reports Year End 2015 Financial Results
• Recro Pharma to Present at the 28th Annual ROTH Conference
• Recro Pharma Appoints Fred Graff as Chief Commercial Officer
• Recro Pharma Initiates Second Pivotal Phase III Clinical Trial of IV Meloxicam for Acute Postoperative Pain
• Recro Pharma Initiates Pivotal Phase III Clinical Trial of IV Meloxicam for Acute Postoperative Pain
• Recro Pharma to Present at NobleCon12 Investor Conference
• Recro Pharma Reports Positive Top-Line Results for Phase II Clinical Trial of IV Meloxicam
• Recro Pharma Appoints Stewart McCallum, MD, as Chief Medical Officer
• Recro Pharma to Present at the 2015 Piper Jaffray Healthcare Conference
• Recro Pharma Reports Third Quarter 2015 Financial Results
• Recro Pharma to Participate in Upcoming Investor Conferences
• Recro Pharma Provides Pipeline Update
• Recro Pharma Appoints Karen A. Flynn to Its Board of Directors
• Recro Pharma Announces Presentations at PAINWeek 2015
• Recro Pharma Reports Second Quarter 2015 Financial Results
• Recro Pharma Announces Additional Information for Phase II Clinical Trial of Dex-IN
• Recro Pharma Appoints Scott Rizzo as General Manager
• Recro Pharma Announces Positive Top-Line Results for Phase II Clinical Trial of Dex-IN
• Recro Pharma Completes $16 Million Private Financing
• Recro Pharma Announces $16 Million Financing
• Recro Pharma to Present at the Jefferies 2015 Global Healthcare Conference
• Recro Pharma Reports First Quarter 2015 Financial Results
• Recro Pharma Completes Acquisition of IV/IM Meloxicam and cGMP Manufacturing Facility and Business Unit From Alkermes
• Recro Pharma Announces Update on On-Going Phase II Clinical Trial of Dex-IN for Treatment of Acute Pain on Day 1 Following Surgery
• Recro Pharma Reports Fourth Quarter and Full Year 2014 Financial Results
• Recro Pharma to Acquire IV/IM Meloxicam and Gainesville, GA GMP Manufacturing Facility and Business Unit From Alkermes
• Recro Pharma Enters Into Common Stock Purchase Agreement With Aspire Capital
• Recro Pharma to Present at the 17th Annual BIO CEO & Investor Conference
• Recro Pharma Reports Third Quarter 2014 Financial Results
• Recro Pharma Announces Dosing of First Patient in Phase II REC-14-013 Clinical Trial of Dex-IN for Treatment of Acute Pain on Day 1 Following Surgery
• Recro Pharma to Present at the 2014 Aegis Healthcare & Technology Conference
• Recro Pharma Provides Clinical Strategy Update Following Interim Analysis for Phase IIb Clinical Trial of Dex-IN
• Recro Pharma Reports Second Quarter 2014 Financial Results
• Recro Pharma Added to Russell Microcap(R) Index
• Recro Pharma Announces Dosing of First Patient in Phase IIb Clinical Trial of Dex-IN for Treatment of Acute Pain Following Surgery
• Recro Pharma Reports First Quarter 2014 Financial Results
• Recro Pharma Announces New Board Members
• Recro Pharma Announces Closing of Initial Public Offering
• Recro Pharma Announces Full Exercise of Underwriters' Option to Purchase Additional Shares
• Recro Pharma Announces Pricing of Its Initial Public Offering

Thought Leadership

• CPhI North America: Proactive Planning for Supply Chain Risk Management
• Drug Development & Delivery: Outsourcing Formulation Development & Manufacturing: Meeting Demand for Biologics & Specialty Drugs
• Mantell Associates Network Interview: David Enloe
• PharmaCompass: Nitrosamine impurities can be avoided by careful selection of raw materials and processing conditions.
• DCAT: Value Chain Insights — Industry Perspectives: Low-Volume Drugs and Manufacturing
• Modified Release Dosage Forms: Giving New Life to Drugs
• Tablets & Capsules: What to Do If Your Immediate-Release Tablet Scale-Up Batch Fails Dissolution
• American Pharmaceutical Review: Controlled Release Roundtable
• Tablets & Capsules: Ask an Expert: Immediate-Release Tablet Scale-Up
• DCAT: Value Chain Insights — Tracking Expansions in High-Potency Manufacturing
• Pharmaceutical Outsourcing: Oral Solid Dosage Manufacturing Roundtable
• Drug Development & Delivery: Outsourcing Formulation Development & Manufacturing: Specialized Capabilities for Small & Large Molecules
• Georgia Bio — The Unsung Link Between Drug Discovery and Patients: Enter the CDMO
• Tablets & Capsules: Formulating Drug Products With Complex APIs
• Pharmaceutical Technology: Best Practices for Design and Operation of Multiproduct Manufacturing Facilities
• Drug Development & Delivery: Outsourcing Analytical Testing: Novel Services Elicit Consistent, Quantifiable, & Faster Results
• Tablets & Capsules: CDMO Turns to Rotary Granulation Process to Solve Complex Reformulation Challenge
• Tablets & Capsules — More Questions and Answers: Formulating With Complex APIs
• Tablets & Capsules: Developing Oral Controlled-Release Drug Products
• Drug Development & Delivery: Outsourcing Formulation Development & Manufacturing: CDMOs Shift to Offer More Specialized Services
• Tablets & Capsules — Ask an Expert: Modifying a Previously Approved Sustained-Release Formulation
• Tablets & Capsules — Call in the Experts: The Benefits of Outsourcing Product Testing and Analysis
• Drug Development & Delivery: Outsourcing Analytical Testing: The Gateway to Drug Manufacturing

Events

• CPhI North America
• GCSG 2021 US Virtual Conference
• How to Select the Right Polymers for your Modified Release Tablet or Capsule
• H.C. Wainwright Global Life Science Conference
• Virtual Booth
• AAPS 2020 PharmSci 360 - Now Digital, Schedule a Virtual Meeting!
• Biocom Global Life Science Partnering Conference 2020
• American Pharma Outsourcing Summit 2020
• BIO 2020 - Now Digital, Schedule a Virtual Meeting!
• DCAT Week 2020 – Cancelled, Schedule a Virtual Meeting!
• 44^th International GMP Conference
• Controlled Release Society - Now Digital, Schedule a Virtual Meeting!
• Ohio Bioscience Expo & Showcase
• Controlled & Modified Drug Release Summit
• Georgia Bio Innovation Summit
• Georgia Bio Member Meeting: Innovation in Drug Development
• Outsourced Pharma San Diego
• Partnership Opportunities in Drug Delivery
• BIO 2019
• Clinical Trial Supply West Coast
• Outsourced Pharma Boston
• Drug Delivery West
• World Orphan Drug Conference USA
• 8th Annual Clinical Trial Supply New England
• UGA International GMP Conference
• BIOCOM Global Life Science Partnering Conference
• AAPS PharmSci 360
• American Pharma Outsourcing Summit
• Controlled Release Society
• CPhI North America
• DCAT Week
• AAPS PharmSci 360
• Partnerships in Drug Delivery

Team

• J. David Enloe, Jr.
• Ryan D. Lake
• Scott Rizzo, MBA, MMM
• Richard Sidwell, Ph.D.
• Bill Hirschman
• Shazib Jamil, MBA, MPH
• Carla Lusby, MBA
• Erica Raether, MA, HRM
• David Smithwick, BS
• R. Wayne Wiley, RPh
• Sherida R. Vandiver, MBA, BS
• Cristin Grove
• Sandra Mathis
• Stephen Dress
• Brittany L. Hayes, Ph.D.
• Maura Murphy, Ph.D.
• Neha Shah, Ph.D.